How It Works

IDgenetix pharmacogenetic testing

Making matches on the molecular level

The one-size-fits-all approach to mental health treatment works for no one. IDgenetix is a comprehensive pharmacogenomics (PGx) test that provides personalized medication profiles, tailored to a patient’s unique DNA. The test accounts for more factors that can influence a patient’s response to medication than any other PGx test.

PGx testing helps to determine a person’s metabolic phenotype - how their genes will impact their metabolism of drugs. Some people have genes that cause them to metabolize medicine very rapidly. Individuals with gene mutations associated with rapid metabolism may require higher doses of a medicine for it to have the same effect as someone with a lower metabolism. They may also experience fewer side effects.

IDgenetix PGx test integrates an individual report based on:

  • 1
    Drug-gene interactions

    97% of individuals carry actionable genetic variants affecting drug metabolism

  • 2
    Drug-drug interactions

    52% of patients take more than one medication

  • 3
    Lifestyle factors and environment

    Lifestyle and demographic factors may affect a patient’s ability to metabolize medications or increase the risk of side effects

Create personalized medication profiles

The IDgenetix test includes 127 medications and 26 drug classes in 10 disease indications. Bioinformatics algorithmic screening assesses and interprets complex factors to generate an easy-to-read report, personalized to the patient.

  • 10 conditions profiled:
    • ADHD, Anxiety, Arthritis, Bipolar Disorder, Depression, Migraine, Musculoskeletal Pain, Neuropathic Pain, Psychosis, Seizure Disorder
  • 26 drug classes
  • 127 medications
  • 15 genes
  • 73 alleles

Scientific evidence

  • Improved response and remission rates in patients receiving IDgenetix-guided medication management for major depressive disorder

    20 May 2023

    In the study, patients whose medication management was guided by IDgenetix achieved a 35% increase in medication response and a 64% increase in remission compared to patients whose medication was not guided by the test

    Cao F, Maciel A, Wosnik K, et al.

    Read More

  • IDgenetix-Guided Medication Management for Major Depressive Disorder: Confirmation of Randomized Controlled Trial Outcomes by Real-World Evidence

    09 Nov 2023

    This study compared the clinical outcome results from Bradley et al. (2018) with real-world evidence. Patient response and remission rates strongly aligned between both studies.

    Cao F, Hanson A, Cook R

    Read More

  • The Importance of Incorporating Drug-Drug Interactions and Lifestyle Factors in Pharmacogenomics-Guided Medication Management for Patients With Major Depressive Disorder in a Randomized Controlled Trial.

    06 Sep 2023

    In this study, drug-drug interactions accounted for 32% of all IDgenetix-guided drug recommendations, and lifestyle factors accounted for 11%. Incorporating these non-genetic factors in IDgenetix testing significantly impacts the number of drug recommendations and improves remission rates in patients with moderate to severe depression.

    Cao F, Hanson A, Cook R, et al.

    Read More

  • Evaluating treatment outcomes in pharmacogenomic-guided care for major depression: A rapid review and meta-analysis

    01 Mar 2023

    Pharmacogenomic (PGx) testing may increase the probability of remission and response in patients with major depressive disorder (MDD) undergoing pharmacotherapy.

    Bunka M, et al.

    Read More
View All

Clinically validated in depression and anxiety

In a randomized controlled trial (RCT), patients with depression and patients with anxiety whose doctors received IDgenetix testing guidance had a better chance of responding to medication and achieving remission.

Patients with severe depression who received IDgenetix-guided treatment:

  • Were 2x more likely to respond to treatment
  • Had 2.5x higher rates of remission

Patients with anxiety who received IDgenetix-guided treatment were more likely to respond to treatment.

Study design

Randomized Controlled Trial (RCT)

  • 685 participants with depression and/or anxiety
  • Double-blinded
  • Treated by Psychiatrists, Internal Medicine, OBGYN, Family Medicine
  • 20 independent clinical sites
  • 4, 8 and 12-week efficacy using HAM-D
Read More
View of a patient's clasped hands as they sit, listening to their clinician

Get started with IDgenetix

Order Test
Click to learn more
Next up

Order Process & Results

View More